In the EMPA-REG OUTCOME trial, a large randomized controlled clinical trial, the highly selective SGLT2 inhibitor empagliflozin significantly reduced the risk of three-point major adverse CV events, cardiovascular death, heart failure hospitalization and composite renal outcomes in patients with type 2 diabetes (T2D) with established cardiovascular disease2. Here, SLC5A2 is linked to type 2 diabetes mellitus.